RMO No. 20-2022 tightens ATRIG processing for VAT-exempt imported medicines, requiring complete documents and exact FDA description matching.

Importers of VAT-exempt medicines for diabetes, high cholesterol, hypertension, cancer, mental illness, tuberculosis, and kidney diseases must now be more exacting with their ATRIG applications: the BIR will stamp an application as received only when the supporting documents are complete and no discrepancy is noted. For pharmaceutical importers, customs brokers, hospitals, distributors, and corporate taxpayers importing qualified VAT-exempt medicines, this means the one-day ATRIG processing period begins only after the application is complete and the drug or medicine description matches the Food and Drug Administration listing exactly.

What RMO No. 20-2022 Changed

RMO No. 20-2022 modified the guidelines and procedures for the issuance of Authority to Release Imported Goods, or ATRIG, for VAT-exempt drugs and medicines covered by Section 109(AA) of the National Internal Revenue Code of 1997, as amended by Republic Act No. 11534, also known as the CREATE Act. The issuance specifically applies to VAT-exempt importations of prescribed drugs and medicines for diabetes, high cholesterol, hypertension, cancer, mental illness, tuberculosis, and kidney diseases.

The key operational change is that the BIR’s one-day processing rule for ATRIG applications remains, but with a stricter starting point. The ATRIG shall be processed, approved, and issued within one day from the time of actual receipt of the application where the application is supported by complete documents and there is no legal or factual issue on the taxability of the imported article. However, RMO No. 20-2022 now expressly provides that the BIR will only stamp the application as received when documentation is complete and no discrepancy is noted.

This matters because businesses often focus on the one-day processing language without accounting for the intake rules. Under the modified rule, an incomplete or inconsistent ATRIG application may not even be treated as received. The practical consequence is delay in release, possible customs processing issues, and disruption of the supply chain for qualified VAT-exempt medicines.

Who Is Affected by the Modified ATRIG Rules

RMO No. 20-2022 is most relevant to pharmaceutical companies, importers, distributors, hospitals, healthcare institutions, customs brokers, and large taxpayers that import VAT-exempt drugs and medicines covered by Section 109(AA) of the Tax Code. It also affects accountants, tax managers, and compliance officers responsible for preparing ATRIG applications, reconciling product descriptions, and coordinating with the BIR, Bureau of Customs, and Food and Drug Administration.

The issuance is especially important for taxpayers importing drugs and medicines for the covered illnesses: diabetes, high cholesterol, hypertension, cancer, mental illness, tuberculosis, and kidney diseases. If the imported goods fall outside these categories, the modified procedures under RMO No. 20-2022 for Section 109(AA) VAT-exempt medicines should not be assumed to apply.

For large taxpayers, ATRIGs processed by the Large Taxpayers Assistance Division II remain subject to approval by the Assistant Commissioner for Large Taxpayers Service. For ATRIGs processed by Revenue District Offices and Excise Tax Areas co-located in their respective Regional Offices, approval is made by the Regional Director. RMO No. 20-2022 also clarifies that Revenue District Officers approve ATRIGs for RDOs having jurisdiction over the port of entry that are not co-located in the Regional Offices.

Exact FDA Description Is Now Critical

The most important compliance point under RMO No. 20-2022 is the requirement that the description of the drugs or medicines in the ATRIG application must be exactly the same as the published list by the Food and Drug Administration. If the description does not match the FDA listing, the Revenue District Office will not accept the application. The applicant must settle the issue or discrepancy with the FDA.

This is a practical warning to importers and brokers: product descriptions, brand names, generic names, dosage forms, strengths, and other identifying details should be reviewed before filing. A minor mismatch between the ATRIG application and the FDA-published list may prevent the application from being accepted. The BIR will not simply accept the application and resolve the discrepancy during processing. The taxpayer must first correct or settle the discrepancy with the FDA.

Searches such as “RMO 20-2022 ATRIG VAT exempt medicines,” “BIR ATRIG requirements for imported drugs,” “VAT exempt medicines Philippines CREATE Act,” “FDA listing ATRIG application,” and “Section 109(AA) Tax Code VAT exemption” are therefore directly relevant for companies preparing importation documents for qualified medicines.

Key Deadlines and Processing Timelines

The one-day processing timeline remains the headline compliance feature. The ATRIG shall be processed, approved, and issued within one day from actual receipt of the application, provided that the application is supported by complete documents and there is no legal or factual issue on the taxability of the imported article.

However, taxpayers should treat “actual receipt” as a controlled compliance event. The BIR will only stamp the ATRIG application as received when the documentation is complete and no discrepancy is noted. In practice, the one-day period should not be counted from the taxpayer’s first attempt to submit documents if the BIR finds missing requirements or a mismatch in the drug or medicine description.

RMO No. 20-2022 also changes the post-approval release workflow. Upon receipt of the duly approved ATRIG, the releasing officer must send a scanned copy by electronic mail to the dedicated email of the Bureau of Customs Revenue Collector handling the release of the imported items. This scanned copy may be sufficient for the Bureau of Customs to process the release of the imported goods.

The scanned copy must also be sent to the taxpayer or authorized representative, including brokers, provided there is a Special Power of Attorney or Secretary’s Certificate authorizing the applicant to process and receive a photocopy of the ATRIG, and provided that the official email where the scanned copy will be sent is identified.

Another important modification is the timing for transmitting original ATRIG copies to the Bureau of Customs. Instead of requiring the transmittal letter and original approved ATRIGs to be sent not later than 12:00 noon of the following day, RMO No. 20-2022 provides for sending the transmittal letter and original copies of approved ATRIGs directly to the Bureau of Customs on a weekly basis through a designated Revenue Officer.

Penalties and Risks for Non-Compliance

RMO No. 20-2022 does not prescribe a separate schedule of fines or penalties in the text of the modified ATRIG procedures. The immediate consequence of non-compliance is operational: the application may not be accepted, may not be stamped as received, and may not enter the one-day processing period. Where the description of the drug or medicine does not exactly match the FDA listing, the RDO will not accept the application and the applicant must resolve the discrepancy with the FDA.

For businesses, the more serious risk is commercial delay. Without timely ATRIG processing, the release of imported VAT-exempt medicines may be affected. This can disrupt inventory planning, hospital supply commitments, distribution schedules, and cash flow assumptions tied to VAT-exempt importation. Customs brokers and corporate tax teams should therefore treat ATRIG preparation as a pre-importation compliance priority, not a last-minute release document.

Practical Steps for Importers, Brokers, and Tax Teams

First, confirm that the imported goods are drugs or medicines covered by Section 109(AA) of the Tax Code, as amended by RA No. 11534, and that they relate to diabetes, high cholesterol, hypertension, cancer, mental illness, tuberculosis, or kidney diseases. RMO No. 20-2022 is specific to VAT-exempt drugs and medicines under this statutory category.

Second, reconcile the ATRIG application description against the FDA-published listing before submission. The description in the application must be exactly the same as the FDA listing. Any mismatch should be resolved with the FDA before filing with the BIR, because the RDO will not accept the application if the descriptions do not match.

Third, complete the documentation before presentation to the BIR. Since the BIR will stamp the application as received only when documentation is complete and no discrepancy is noted, taxpayers should use an internal checklist and require the broker, regulatory team, and tax team to sign off before filing.

Fourth, prepare proper authority for representatives. If a broker or other authorized representative will receive the scanned ATRIG, the taxpayer should prepare the appropriate Special Power of Attorney or Secretary’s Certificate authorizing the applicant to process and receive a photocopy of the ATRIG. The official email address for receiving the scanned copy should be clearly identified.

Fifth, coordinate with the Bureau of Customs release process. Because the scanned ATRIG sent by email to the dedicated email of the BOC Revenue Collector may be sufficient for processing the release of imported goods, importers should ensure that their customs broker monitors both BIR approval and BOC receipt of the scanned ATRIG.

How Ablola, Saribong & Gueco Can Assist

ATRIG delays often arise from preventable document issues: incomplete submissions, inconsistent product descriptions, unclear representative authority, or failure to align BIR, BOC, and FDA requirements. For businesses importing VAT-exempt medicines, these are not merely clerical concerns. They affect customs release, VAT exemption treatment, supply chain timing, and regulatory compliance.

Ablola, Saribong & Gueco assists importers, distributors, healthcare businesses, pharmaceutical companies, and corporate taxpayers in reviewing ATRIG requirements, preparing authority documents, coordinating tax compliance positions, and resolving BIR-related issues involving VAT-exempt importations. For assistance with RMO No. 20-2022, ATRIG applications, VAT-exempt medicines, and BIR compliance procedures, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *